Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)

This will be an open-label, single arm, phase IIa study in subjects with metastatic
pancreatic adenocarcinoma.

The study will include 30 subjects with unresectable metastatic pancreatic adenocarcinoma.

The study consists of two periods:

- Monotherapy period: One week, with BL-8040 administered daily on days 1-5.

- Combination therapy: Three week cycles of a combination of BL-8040 administered three
times a week (TIW) and pembrolizumab administered once every three weeks.

Subjects with metastatic pancreatic adenocarcinoma will be enrolled and receive BL-8040
monotherapy for five days followed by a combination treatment of BL-8040 and pembrolizumab.
During the monotherapy period, eligible subjects will receive daily subcutaneous (SC)
injections of BL-8040 (1.25 mg/kg) on days 1 - 5.

From Day 8 subjects will begin a combination period consisting of treatment with SC BL-8040
(1.25 mg/kg) three times a week (TIW) and pembrolizumab (200mg) once every three weeks. The
combination therapy will continue for up to two years, or until progression, clinical
deterioration or early termination, whichever comes first.

Inclusion Criteria:

1. 18 years and older.

2. Patients must sign a written informed consent prior to entering the study.

3. Histologically confirmed (either previously or newly biopsied) metastatic unresectable
pancreatic adenocarcinoma, including with intraductal papillary mucinous neoplasm.

4. Have measurable disease (≥ 1 measurable lesion) based on RECIST v1.1 as determined by
the site study team. Tumor lesions situated in a previously irradiated area are
considered measurable if progression has been demonstrated in such lesions.

5. Subjects with one or more prior treatments for their pancreatic cancer.

6. Willing to submit an evaluable tumor tissue sample, preferably from a liver
metastasis, unless tumor is considered inaccessible or biopsy is otherwise considered
not in the subject's best interest

7. Complete resolution of toxic effect(s) of the most recent prior chemotherapy to Grade
1 or less (except alopecia). If the subject received major surgery or radiation
therapy of > 30 Gy, they must have recovered from the toxicity and/or complications
from the intervention.

8. ECOG status ≤1.

9. Life expectancy of at least 3 months.

10. Adequate organ function at baseline as defined below. All laboratory assessments
should be performed within 10 days of treatment initiation.

1. Hematological:

- WBC ≥ 2,500/mm^3

- Absolute neutrophil count ≥ 1000 /mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥9 g/dL or ≥5.6 mmol/L

- Hematocrit ≥30%

2. Renal function:

Creatinine ≤1.5x ULN OR measured or calculated creatinine clearance (Glomerular
filtration rate [GFR]) can also be used in place of creatinine or CrCl) > 60
mL/min for subjects with creatinine levels > 1.5x institutional ULN

3. Hepatic function:

- Total Bilirubin: ≤1.5xULN OR Direct bilirubin ≤ULN for subjects with total
bilirubin levels >1.5xULN

- AST (SGOT) and ALT (SGPT): ≤2.5xULN OR ≤5xULN for subjects with liver
metastases

4. Coagulation:

- INR or PT: ≤1.5xULN unless subject is receiving anticoagulant therapy, as
long as PT or PTT is within therapeutic range of intended use of
anticoagulants

- aPTT: ≤1.5xULN unless subject is receiving anticoagulant therapy as long as
PT or PTT is within therapeutic range of intended use of anticoagulants

11. Subjects must use effective contraception:

1. Female subjects must be of non-childbearing potential or, if of childbearing
potential, must have a negative urine or serum pregnancy test within 72 hours
prior to taking study medication. If the urine test is positive or cannot be
confirmed as negative, a serum pregnancy test will be required. The serum
pregnancy test must be negative for the subject to be eligible. Non-childbearing
potential is defined as (by other than medical reasons):

- ≥45 years of age and has not had menses for over 2 years

- Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a
Follicle Stimulating Hormone (FSH) value in the postmenopausal range upon
pretrial (screening) evaluation

- Post hysterectomy, bilateral oophorectomy, bilateral salpingectomy or
bilateral tubal ligation at least 6 weeks prior to screening. Documented
hysterectomy or oophorectomy must be confirmed with medical records of the
actual procedure or confirmed by ultrasound. Tubal ligation must be
confirmed with medical records of the actual procedure otherwise the subject
must be willing to use two adequate barrier methods throughout the study,
starting with the screening visit through 120 days after the last dose of
study therapy. Information must be captured appropriately within the site's
source documents

2. Male subjects must agree to use an adequate method of contraception starting with
the first dose of study therapy through 120 days after the last dose of study
therapy.

Exclusion Criteria:

1. Has pancreatic tumor other than adenocarcinoma, including: acinar cell carcinoma,
pancreaticoblastoma, malignant cystic neoplasms, endocrine neoplasms, squamous cell
carcinoma. Vater and periampullary duodenal or common bile duct malignancies.

2. Has an active infection requiring systemic therapy or uncontrolled infection.

3. Has a known additional malignancy that is progressing or requires active treatment.
Exceptions are adequately treated basal cell or squamous cell carcinoma that has
undergone potentially curative therapy, or carcinoma in situ of the cervix.

4. Has an Underlying medical condition that would preclude study participation.

5. Has a disease that is suitable for therapy administered with curative intent.

6. Is currently participating and receiving study therapy or has participated in a study
of an investigational agent and received study therapy or used an investigational
device within 4 weeks of the first dose of treatment.

7. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
other form of immunosuppressive therapy within seven days prior to the first dose of
trial treatment. The use of physiologic doses of corticosteroids may be approved after
consultation with the Sponsor.

8. Has had a prior anti-cancer monoclonal antibody within 4 weeks prior to study Day 1 or
who has not recovered (i.e., ≤ Grade 1 or at baseline) from AEs due to agents
administered more than 4 weeks earlier.

9. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
within 2 weeks prior to study Day 1 or has not recovered (i.e., ≤ Grade 1 or at
baseline) from AEs due to a previously administered agent .

10. An active autoimmune disease that has required systemic treatment in the two years
preceding the study (i.e. with the use of disease-modifying agents, corticosteroids or
immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,
etc.) is not considered a form of systemic treatment.

11. Has received transfusion of blood products (including platelets or red blood cells) or
administration of colony stimulating factors (including G-CSF, GM-CSF or recombinant
erythropoetin) within four weeks prior to study Day 1.

12. Has a history of (non-infectious) pneumonitis that required steroids or current
pneumonitis.

13. Has a history of interstitial lung disease.

14. O2 saturation < 92% (on room air).

15. Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the trial, interfere with the subject's
participation for the full duration of the trial, or is not in the best interest of
the subject to participate, in the opinion of the treating Investigator.

16. Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.

17. Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the screening visit through 120 days
after the last dose of trial treatment. Women with a positive pregnancy test within 72
hours from baseline.

18. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or if
the subject has previously participated in Merck MK-3475 clinical trials.

19. Has a known history of HIV (HIV 1/2 antibodies).

20. Has known active Hepatitis B (e.g., Hepatitis B Surface Antigen [HBsAg] reactive) or
Hepatitis C (e.g., Hepatitis C Virus [HCV] RNA [qualitative] is detected).

21. Has known history of Chronic Hepatitis B or C

22. Has received a live vaccine within 30 days of the planned start of study therapy.
Seasonal flu vaccines that do not contain live virus are permitted.

23. Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis. Note: Subjects with previously treated brain metastases may participate
provided they are stable (without evidence of progression by imaging using the
identical imaging modality for each assessment, either MRI or CT scan, for at least
four weeks prior to the first dose of trial treatment and any neurologic symptoms have
returned to baseline), have no evidence of new or enlarging brain metastases, and are
not using steroids for at least 7 days prior to trial treatment. This exception does
not include carcinomatous meningitis which is excluded regardless of clinical
stability.